StoryResearch
Kelonia presents Phase 1 ASCO 2026 data: durable MRD-negative responses, manageable safety in multiple myeloma
Kelonia Therapeutics presented updated Phase 1 inMMyCAR trial data at ASCO 2026, demonstrating durable MRD-negative responses and a favorable safety profile for KLN-1010 in heavily pretreated patients with relapsed/refractory multiple myeloma. The data reinforce the potential for KLN-1010 to transform CAR-T therapy by eliminating manufacturing complexity and reducing treatment burden.
- MRD-negative responses remained durable through the presented follow-up period.
- No high-grade immune-related adverse events (CRS, ICANS) observed; safety profile superior to traditional ex vivo CAR-T cell therapies.
- Treatment course compressed from 4-6 weeks (ex vivo CAR-T) to under 3 weeks (KLN-1010).
- Potential to dramatically broaden CAR-T cell therapy access by eliminating manufacturing bottlenecks.